Biotech company raises $31m to unlock biology behind major diseases

Biotechnology company Fluidic Analytics has raised $31 million to help it develop products that could provide insight into the way diseases develop.

The company will use the funding to continue to develop its products for characterising proteins and their behaviour and will work towards a commercial roll-out of its lab-tools pipeline. It will also develop high-value clinical applications of its technology.

Fluidic Analytics’ portfolio is based on a proprietary technology platform from the University of Cambridge which is designed to give deep insights into the way proteins fold, aggregate and interact by characterising them in a solution – precisely as they exist in the body.

Examining the way proteins behave in the body can help scientists understand how diseases develop, identify the way that drugs interact with their targets and develop new methods for matching the right treatment to the right patients.

Whilst DNA can provide insights into what is likely to happen over a lifetime, proteins can tell us what is happening at the current moment. However, existing tools for protein characterisation have hampered our understanding of the underlying biology in disease and health in real time.

Advanced technologies can help researchers understand the mechanisms of conditions like Alzheimer’s and help manufacturers develop more effective drugs.

Andrew Lynn, chief executive officer, Fluidic Analytics, said: “This financing will power the global commercial launch of our Fluidity One system and enable our team to bring our next two lab-tools products to market. It will also allow us to advance a number of high-potential clinical applications that could help us make an even bigger impact on the world. We are delighted to be working with investors who share our vision of helping people everywhere make better decisions about how diseases are diagnosed, treatments are developed, and personal well-being is maintained."